Read by QxMD icon Read


Laura Verbree-Willemsen, Ya-Nan Zhang, Crystel M Gijsberts, Arjan H Schoneveld, Jiong-Wei Wang, Carolyn S P Lam, Floor Vernooij, Michiel L Bots, Linda M Peelen, Diederick E Grobbee, Joel S Raichlen, Dominique P V de Kleijn
BACKGROUND: Statins are thought to have pleiotropic properties, including anticoagulant effects, in addition to reducing lipoprotein (LDL) levels. Plasma extracellular vesicles (EVs) are small bilayer membrane vesicles involved in various biological processes including coagulation. Since subsets of EVs in the LDL plasma fraction (LDL-EVs) correlate with thrombin activity, we hypothesized that changes in LDL-EVs after statin therapy may differ from that of serum levels of coagulation proteins, providing insight into the effects of statins on coagulation...
May 26, 2018: International Journal of Cardiology
Nyarai D Soko, Collen Masimirembwa, Collet Dandara
OBJECTIVE: This study describes a restriction fragment polymorphism protocol for rapidly screening the polymorphism SLCO1B1 c.1929A>C in genomic DNA samples. The polymorphism SLCO1B1 c.1929A>C has been associated with increased activity resulting in increased hepatic uptake of drugs. Currently SLCO1B1 c.1929A>C is genotyped using direct sequencing techniques and 5' nuclease based assays which can be cost prohibiting in resource limited settings. The aim of this study therefore was to design and validate a cost effective RFLP for genotyping the SLCO1B1 c...
June 14, 2018: BMC Research Notes
E O Vershinina, A N Repin, M S Timofeev, V V Udut
PURPOSE OF THE STUDY: To compare the effect of loading doses of atorvastatin and rosuvastatin on the value of the acute kidney injury and acute inflammatory response to elective percutaneous coronary interventions. MATERIALS AND METHODS: An open prospective comparative study included 68 patients referred for elective percutaneous coronary intervention (PCI). At baseline, all patients had been taking statins for a long time as a standard lipid-lowering therapy. The first group included 33 patients who received a loading dose of 80 mg of atorvastatin (As) 12 hours before the intervention with saving this dose for 2-6 days...
2018: Kardiologiia
Kazuya Ishida, Mohammed Ullah, Beata Toth, Viktoria Juhasz, Jashvant D Unadkat
For successful in vitro -to- in vivo extrapolation (IVIVE) of hepatic drug uptake and DDI, it is important to characterize the kinetic properties of the individual transporters involved, their fraction (ft) contribution to hepatic uptake, and their selective inhibitors. Here, we characterized the in vitro transport kinetics of two model drugs, rosuvastatin (RSV) and olmesartan acid (OLM), by rat hepatic organic anion transporting polypeptides (Oatp1a1, 1a4 and 1b2) and identified selective inhibitors of these transporters...
June 11, 2018: Drug Metabolism and Disposition: the Biological Fate of Chemicals
Rachel E Kosa, Sarah Lazzaro, Yi-An Bi, Brendan Tierney, Dana Gates, Sweta Modi, Chester Costales, A David Rodrigues, Larry M Tremaine, Manthena V Varma
We aim to establish an in vivo preclinical model to enable simultaneous assessment of inhibition potential of an investigational drug on clinically relevant drug transporters, organic anion transporting polypeptide (OATP)1B, breast cancer resistance protein (BCRP), P-glycoprotein (P-gp) and organic anion transporter (OAT)3. Pharmacokinetics of substrate cocktail consisting of pitavastatin (OATP1B substrate), rosuvastatin (OATP1B/BCRP/OAT3), sulfasalazine (BCRP) and talinolol (P-gp) were obtained in cynomolgus monkey - alone or in combination with transporter inhibitors...
June 7, 2018: Drug Metabolism and Disposition: the Biological Fate of Chemicals
Szilvia Veszelka, András Tóth, Fruzsina R Walter, Andrea E Tóth, Ilona Gróf, Mária Mészáros, Alexandra Bocsik, Éva Hellinger, Monika Vastag, Gábor Rákhely, Mária A Deli
Cell culture-based blood-brain barrier (BBB) models are useful tools for screening of CNS drug candidates. Cell sources for BBB models include primary brain endothelial cells or immortalized brain endothelial cell lines. Despite their well-known differences, epithelial cell lines are also used as surrogate models for testing neuropharmaceuticals. The aim of the present study was to compare the expression of selected BBB related genes including tight junction proteins, solute carriers (SLC), ABC transporters, metabolic enzymes and to describe the paracellular properties of nine different culture models...
2018: Frontiers in Molecular Neuroscience
D I Tomilova, Y A Karpov, V V Lopukhova
PURPOSE: To study adherence to therapy with statins and its relation to development of cardio-vascular complications (CVC) in patients with stable angina after elective percutaneous coronary intervention (PCI) at five-year observation. MATERIALS AND METHODS: This study comprised 574 patients with stable angina (81 % men, mean age 60.3 years) hospitalized for elective PCI. All patients were prescribed therapy in accordance with recommendations on management of stable angina including statins...
May 2018: Kardiologiia
Mahboubeh Rezazadeh, Maryam Parandeh, Vajihe Akbari, Zahra Ebrahimi, Azade Taheri
Rosuvastatin (RSV) has been shown to have significant impact on the simulation of bone regeneration after local injection. The current study aimed to develop a localized controlled delivery system from RSV by incorporating RSV-loaded chitosan/chondroitin sulfate (CTS/CS) nanoparticles into thermosensitive Pluronic F127/hyaluronic acid (PF127/HA) hydrogel. RSV-loaded CTS/CS nanoparticles were prepared by ionic gelation and the impact of various formulation variables was assessed using the Box-Behnken design...
June 4, 2018: Pharmaceutical Development and Technology
Woohyeun Kim, Yeonyee E Yoon, Sung-Hee Shin, Jang-Whan Bae, Bum-Kee Hong, Soon Jun Hong, Ki Chul Sung, Seung Hwan Han, Weon Kim, Moo-Yong Rhee, Sang-Hyun Kim, Sang Eun Lee, Min Su Hyon, Gyo-Seung Hwang, Jang Won Son, Jang-Young Kim, Min Kyu Kim, Sang Wook Kim, Jae-Hyeong Park, Jin Ho Shin, Chang Gyu Park
PURPOSE: The aim of this study was to evaluate the safety and efficacy of combination treatment of rosuvastatin with ezetimibe in patients with primary hypercholesterolemia. METHODS: This multicenter, randomized, double-blind study comprised a main study and an extension study. In the main study, the efficacy and safety of a combination of rosuvastatin (5, 10, and 20 mg) with ezetimibe (10 mg) were compared with those of rosuvastatin (5, 10, and 20 mg) alone. The subjects who achieved the National Cholesterol Education Program Adult Treatment Panel III LDL-C goal in the main study and agreed to a further study were enrolled for the extension study...
May 29, 2018: Clinical Therapeutics
Hyunbeom Lee, Jong Min Choi, Joo-Youn Cho, Tae-Eun Kim, Hwa Jeong Lee, Byung Hwa Jung
Rosuvastatin is a statin used to treat metabolic syndrome conditions, such as hyperlipidemia. It is relatively safe; however, fatal rhabdomyolysis or skeletal myopathy can sometimes occur. Therefore, to investigate the overall effects of rosuvastatin, including lipid lowering and adverse effects, metabolic profiling was performed using metabolomics and lipidomics after rosuvastatin administration. Specifically, the metabolic profiles between healthy subjects and patients with hyperlipidemia were compared and the metabolic changes related to the mechanism of the drug effect were proposed...
May 28, 2018: Chemistry and Physics of Lipids
Ling Wang, Rong Lin, Langtao Guo, Meiman Hong
The present study aimed to investigate whether pretreatment with rosuvastatin (RS) can provide cardioprotection in a myocardial ischemia/reperfusion (MI/R) model. The protective effect of RS on myocardial oxygen‑glucose deprivation/reperfusion (OGD/R) injury was also evaluated by upregulating peroxisome proliferator‑activated receptor‑γ (PPAR‑γ). In the present study, MI/R model was established and activities of superoxide dismutase (SOD), lactate dehydrogenase (LDH), creatine kinase‑muscle/brain (CK‑MB), malondialdehyde (MDA), and troponin I/T were measured...
May 23, 2018: Molecular Medicine Reports
Jøran Hjelmesæth, Anders Åsberg, Shalini Andersson, Rune Sandbu, Ida Robertsen, Line Kristin Johnson, Philip Carlo Angeles, Jens Kristoffer Hertel, Eva Skovlund, Maria Heijer, Anna-Lena Ek, Veronica Krogstad, Tor-Ivar Karlsen, Hege Christensen, Tommy B Andersson, Cecilia Karlsson
INTRODUCTION: Roux-en-Y gastric bypass (GBP) is associated with changes in cardiometabolic risk factors and bioavailability of drugs, but whether these changes are induced by calorie restriction, the weight loss or surgery per se, remains uncertain. The COCKTAIL study was designed to disentangle the short-term (6 weeks) metabolic and pharmacokinetic effects of GBP and a very low energy diet (VLED) by inducing a similar weight loss in the two groups. METHODS AND ANALYSIS: This open, non-randomised, three-armed, single-centre study is performed at a tertiary care centre in Norway...
May 29, 2018: BMJ Open
Yanshao Liu, Tao Chen, Jieyong Xing
The effect of rosuvastatin on the expression of candidate gene polypeptide N-acetylgalactosaminyltrans ferase 3 ( GALNT3 ) in atherosclerosis was studied. Sixty Wistar rats were randomly divided into the control (n=20), model (atherosclerosis group, n=20) and administration (rosuvastatin group, n=20) groups. The atherosclerosis model was established via injecting D3.6 million units of vitamin per kilogram of body weight and then the rats were fed with high-fat diet for 6 weeks. The total cholesterol, serum triglyceride and nitric oxide contents were detected using the kits, the morphological changes in thoracic aorta were observed via hematoxylin and eosin (H&E) staining, the mRNA expression of candidate gene GALNT3 was detected via reverse transcription-polymerase chain reaction (RT-PCR), and the protein expression of candidate gene GALNT3 was detected via western blot analysis...
June 2018: Experimental and Therapeutic Medicine
Mosepele Mosepele, Onkabetse J Molefe-Baikai, Steven K Grinspoon, Virginia A Triant
PURPOSE OF REVIEW: HIV-infected patients face an increased risk for cardiovascular disease (CVD), estimated at 1.5- to 2-fold as compared to HIV-uninfected persons. This review provides a recent (within preceding 5 years) summary of the role of statin therapy and associated role in CVD risk reduction among HIV-infected patients on anti-retroviral therapy. RECENT FINDINGS: Statins remain the preferred agents for reducing risk for CVD among HIV-infected populations based on guidance extrapolated from general population (HIV-uninfected) cholesterol treatment guidelines across different settings globally...
May 26, 2018: Current Infectious Disease Reports
Dileep P, Ipshita S, Ida Grace Kurian, A R Pradeep
AIM: The aim of current study is to explore and compare the clinical efficacy of locally delivered 1.2% Rosuvastatin (RSV) and 1% Metformin (MF) gel as an adjunct to scaling and root planning (SRP) in the treatment of intrabony defects in chronic periodontitis patients. METHOD: A total of ninety volunteers were randomly assigned to three treatment groups; 1. SRP plus placebo gel 2.SRP plus 1.2% RSV gel 3. SRP plus 1% MF gel. Clinical parameters like modified sulcus bleeding index (mSBI), plaque index (PI), pocket probing depth (PD) and clinical attachment level (CAL) were recorded at baseline, 6 and 12 months and the radiological assessment of bone defect fill was done at 6 and 12 months...
May 26, 2018: Journal of Periodontology
Joël Coste, Cécile Billionnet, Annie Rudnichi, Jacques Pouchot, Rosemary Dray-Spira, Philippe Giral, Mahmoud Zureik
Aims The purpose of this study was to investigate the risk of rhabdomyolysis in subjects initiating statin therapy for primary prevention of cardiovascular disease, focusing on the type of statin, dose and time since initiation. Methods and results A nationwide cohort study using French hospital discharge and claims databases was performed, studying subjects from the general population 40-75 years in 2009, with no history of cardiovascular disease and no lipid-lowering drugs during the preceding three-year period, followed for up to seven years...
January 1, 2018: European Journal of Preventive Cardiology
Nashwa Ahmed El-Shinnawy, Sahar Sobhy Abd-Elhalem, Nawal Zakaria Haggag, Gamal Badr
Correction for 'Ameliorative role of camel whey protein and rosuvastatin on induced dyslipidemia in mice' by Nashwa Ahmed El-Shinnawy et al., Food Funct., 2018, 9, 1038-1047.
May 24, 2018: Food & Function
Andromachi Reklou, Michael Doumas, Konstantinos Imprialos, Konstantinos Stavropoulos, Dimitris Patoulias, Vasilios G Athyros
Background: Low density lipoprotein cholesterol (LDL-C) and low grade arterial inflammation are key pathogenic factors for atherosclerosis and its manifestation, cardiovascular disease (CVD). Objective: In this narrative review we assessed if decreasing LDL-C levels or inflammation or both is more effective in reducing CVD events. Results: In the Scandinavian Simvastatin Survival Study (4S), all statin trials of the 90s' and the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) the benefit came from the LDL-C reduction...
2018: Open Cardiovascular Medicine Journal
Rabia Nabi, Sahir Sultan Alvi, Rizwan Khan, Shafeeque Ahmad, Saheem Ahmad, M Salman Khan
Non-enzymatic glycation mediated advanced glycation end products (AGEs) generation results in the pathogenesis of diabetic complications and atherosclerotic cardiovascular disease (ASCVD) which is greatly influenced by 3-hydroxy-3-methyl-glutaryl Co-A reductase (HMG-R) activity. HMG-R inhibitors, statins, are well known for reducing mortality and morbidity of ASCVD in patients with diabetes due to their pleiotropic effects independent of cholesterol lowering. Due to distinct chemical structures, various statins may play important role in the inhibition of AGEs mediated pathologies...
May 18, 2018: International Journal of Biological Macromolecules
F T Ageev, Z N Blankova, N S Samsonova
BACKGROUND: The low efficiency of recommended therapy for reducing cardiovascular risk (CV) in patients with arterial hypertension even with an effective blood pressure decrease is often due to the persistence of high blood cholesterol and arterial stiffness. Among the effective ways to achieve the goal of therapy is considered the changing to a single-pill combinations (SPCs) of two antihypertensive drugs and statin. AIM: To assess influence of fixed combination consisted of amlodipine, lisinopril and rosuvastatin to the dynamic of lipid spectrum, blood pressure level and elastic properties of arteries in patients with arterial hypertension and high risk of cardio-vascular complications being transferred from their preceding antihypertensive therapy...
2018: Kardiologiia
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"